A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects With a Functioning Ileostomy

Trial Profile

A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects With a Functioning Ileostomy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2017

At a glance

  • Drugs Ribaxamase (Primary) ; Ceftriaxone; Esomeprazole
  • Indications Clostridium infections
  • Focus Pharmacokinetics
  • Sponsors Synthetic Biologics
  • Most Recent Events

    • 04 Jan 2017 Results from this and other study published in the Antimicrobial Agents and Chemotherapy.
    • 30 Oct 2016 Results of this and one other phase IIa study presented at the IDWeek 2016.
    • 16 May 2016 Results from this trial will be presented at ASM Microbe 2016, according to a Synthetic Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top